Sales and Marketing

Showing 15 posts of 11526 posts found.

biotrial_facility_rennes

Man left brain dead after clinical trial dies in hospital

January 18, 2016 Research and Development, Sales and Marketing Bial, Biotrial, clinical trial

A man left brain dead after a clinical trial in France has died in hospital and five remain in a …
Merck MSD

MSD sues German Merck for using name in US

January 15, 2016 Medical Communications, Sales and Marketing MSD, Merck

MSD says it is filing a lawsuit against the German company Merck “regarding their improper use of the name ‘Merck’ …
Takeda UK

Takeda to bring UK salesforce in-house

January 15, 2016 Medical Communications, Sales and Marketing Takeda, field sales, marketing, sales, sales reps, salesforce

Takeda UK is to bring all of its sales teams and support resources in-house and reintegrate its field salesforce into …
abbvie

AbbVie replaces retiring VP of Western Europe and Canada

January 15, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Esteban Plata, Pascale Richetta

AbbVie has appointed Esteban Plata as vice president of Western Europe and Canada.He replaces Pascale Richetta who is retiring from …
FDA

FDA says no to BioMarin’s Duchenne Muscular Dystrophy drug

January 14, 2016 Medical Communications, Sales and Marketing BioMarin, Duchenne Muscular Dystrophy, FDA, Kyndrisa, drisapersen

The FDA has rejected BioMarin’s Duchenne Muscular Dystrophy (DMD) drug Kyndrisa, saying there was not enough evidence that the drug …
Hospira logo

Pfizer may sell off Hospira unit for $2 billion

January 14, 2016 Manufacturing and Production, Medical Communications, Sales and Marketing Hospira, Pfizer, injectables, pumps

Pfizer is reportedly considering selling Hospira’s infusion pump business for around $2 billion, having acquired the injectable drugs and infusion …
Gavel

US Federal Trade Commission clamps down on pharma ‘pay to delay’ deals

January 14, 2016 Manufacturing and Production, Sales and Marketing Pay to delay, US Supreme Court, antitrust laws, federal trade commission, generic competition, generics, patents, pay for delay

Pharma companies were able to negotiate far fewer so-called ‘pay to delay’ cases as a strategy to stave off generic …
Chemotherapy

A brighter future for the Cancer Drugs Fund?

January 14, 2016 Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Prostate Cancer UK

In November 2015, NICE and NHS England announced proposed changes to the operation of the Cancer Drugs Fund. This is …
dr_robert_califf_image_via_duke_university_school_of_medicine

Senate panel approves Dr Robert Califf as FDA commissioner

January 13, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Dr Robert Califf, FDA, FDA commissioner, Senate

A senate panel has approved president Obama’s nominee Dr Robert Califf to lead the FDA by a clear majority, although …
MSD logo

MSD to acquire Scottish firm IOmet Pharma

January 12, 2016 Research and Development, Sales and Marketing IOMet Pharma, MSD, Merck, Scotland, acquisitions, immuno-oncology, mergers, oncology

US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development …
Eisai

Eisai submits new cancer combo to EMA for approval

January 12, 2016 Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib

Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …
Jinarc

SMC approves first ever treatment for genetic kidney disease

January 12, 2016 Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan

The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …
pfizer_logo

Pfizer raised 100 US drug prices 1 January

January 12, 2016 Manufacturing and Production, Sales and Marketing Allergan, Drug pricing, Lyrica, Pfizer, ibrance, tax inversion

Drugs giant Pfizer raised the prices of more than 100 of its drugs in the US on 1 January,  in …
mark_alles_celgene

Mark Alles is new chief executive of Celgene

January 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Mark Alles

Celgene president and chief operating officer Mike Alles has been promoted to the top job after an executive restructure at …
DMD

The Pharmafocus debate: Can ultra-orphan drugs be made cheaper?

January 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Drug pricing, Duchenne Muscular Dystrophy, Translarne, access to medicines, ataluren, muscular dystrophy, rare disease, ultra orphan drugs, ultra-orphan drugs

The recent reimbursement wrangle between PTC Therapeutics and NICE, the UK healthcare watchdog, has once again raised difficult questions about …
The Gateway to Local Adoption Series

Latest content